AptarGroup Inc.

2 days ago · seekingalpha.com

AptarGroup, Inc. ( ATR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Gael Touya - CEO, President & Director Vanessa Kanu - Executive VP & CFO Conference Call Participants Ghansham Panjabi - Robert W. Baird & Co. Incorporated, Research Division Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Roberts - Raymond James & Associates, Inc., Research Division George Staphos - BofA Securities, Research Division Matthew Larew - William Blair & Company L.L.C.

2 days ago · marketbeat.com

AptarGroup NYSE: ATR reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower margins in Beauty and Closures weighed on results.

3 days ago · zacks.com

AptarGroup (ATR) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.62 per share a year ago.

5 days ago · globenewswire.com

EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research

28 days ago · zacks.com

AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

1 month ago · zacks.com

Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.

2 months ago · seekingalpha.com

AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

2 months ago · prnewswire.com

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results from the STAR-T trial and are expected to form a core component of additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR® Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal in urgent cardiac surgery PRINCETON, N.J., Sept. 2, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative bleeding among patients undergoing urgent coronary artery bypass grafting (CABG) surgery on the blood thinner, ticagrelor (Brilinta®/Brilique®, AstraZeneca).

3 months ago · prnewswire.com

-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Investigational New Drug (IND) application for ATR 1072 and continued achievements under its collaboration with Bristol Myers Squibb (BMS). "Our team continues to execute well, achieving FDA clearance of our IND for ATR 1072 and launching Corventis — Atrium's first Phase 1/2 trial and the first clinical study to evaluate a potential disease-modifying treatment for people living with PRKAG2 syndrome," said Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics.